Division of PhotoCure ASA
Latest From Photocure ASA
Menarini/Stemline, Supernus/US WorldMeds, BioMarin/DiNOAQOR, Adicet/ResTORbio, Vertex/Affinia, Hansoh/NiKang, plus COVID-19 deals in brief and more.
Currently focused on HBV, Altimmune gets preclinical NASH candidate that offers dual agonism of GLP-1 and glucagon receptors. Nimbus expands alliance with Celgene into IO, Merck & Co. partners with Skyhawk.
Established just a year ago, China's Lepu Biotech has raised a mighty $131m to develop immuno-oncology antibodies, while Shanghai-based Asieris has obtained worldwide rights to develop and commercialize Photocure's Cevira for cervical dysplasia.
Keeping Track: Oncology Stays Hot With Besponsa And Lynparza Approvals; New Uses Of Adcetris, Cabometyx Submitted
The latest drug development news and highlights from our US FDA Performance Tracker.
- Diagnostic Imaging Equipment & Supplies
- Radiopharmaceuticals, Contrast Agents
- Therapeutic Areas
- Western Europe
- Parent & Subsidiaries
- PhotoCure ASA
- Senior Management
Daniel Schneider, Pres. & CEO
Erik Dahl, CFO
Inger Ferner Heglund, Acting VP, R&D
Grete Hogstad, VP, Strategic Mktg.
Gry Stensrud, PhD, VP, Tech. Dev. & Operations
Kari Myren, MD, Head, Global Medical Affairs & Clinical Dev.
- Contact Info
Phone: (47) 22 06 22 10